Brokerages Set TapImmune Inc. (NASDAQ:MRKR) Target Price at $9.25
Shares of TapImmune Inc. (NASDAQ:MRKR) have been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.25.
A number of research firms recently commented on MRKR. Zacks Investment Research upgraded TapImmune from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research note on Wednesday, April 3rd. Janney Montgomery Scott began coverage on TapImmune in a research note on Friday, March 1st. They issued a “buy” rating and a $6.22 price target for the company. WBB Securities upgraded TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 price target for the company in a research note on Friday, March 29th. Roth Capital began coverage on TapImmune in a research note on Thursday, May 30th. They issued a “buy” rating and a $10.00 price target for the company. Finally, ValuEngine downgraded TapImmune from a “buy” rating to a “hold” rating in a research note on Friday, June 7th.
Shares of TapImmune stock opened at $6.35 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.73 and a quick ratio of 19.73. The stock has a market cap of $285.19 million, a PE ratio of -3.80 and a beta of 0.04. TapImmune has a 1-year low of $4.18 and a 1-year high of $13.55.
An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. boosted its position in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,919 shares of the company’s stock after acquiring an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned 0.10% of TapImmune worth $303,000 at the end of the most recent quarter. 33.64% of the stock is owned by hedge funds and other institutional investors.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Equity Income
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.